Fisons licensing agreements include deal for Ciba's iralukast; RPR closing in on takeover.
FISONS AND CIBA TO COLLABORATE ON IRALUKAST DEVELOPMENT FOR ASTHMA, Fisons announced Sept. 29. Under the agreement, the companies will collaborate on development and marketing of Ciba's leukotriene d4 antagonist iralukast in a powder formulation for delivery via Fisons' Ultrahaler delivery system. "The arrangements between the parties contemplate and provide for the possibility of further cooperation in relation to follow-up compounds, devices and alternative delivery systems," Fisons added. Iralukast will begin Phase III trials in 1996, Ciba said; the Swiss firm plans to introduce a formulation using its own single-dose dry powder device before completing development of the Ultrahaler formulation.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth